Posters

Tear osmolarity and OCDI in glaucomatous patients under chronic IOP lowering topical medication

Poster Details

First Author: J. Paz Moreno-Arrones SPAIN

Co Author(s):    C. Gutierrez Ortiz   G. Bolivar De Miguel   A. Gonzalez Mesa   M. Teus           

Abstract Details

Purpose:

The purpose of this study is to analyze the prevalence and the severity of dry eye evaluated by tear osmolarity and the OSDI questionnaire in glaucoma (or ocular hypertension patients) under chronic treatment with topical hypotensive drugs, after being instructed to use artificial tears if needed.

Setting:

Service of Ophthalmology, University Hospital Principe De Asturias

Methods:

This is an interventional cohort study of 24 patients with glaucoma and/or ocular hypertensive under chronic therapy with topical antiglaucomatous drugs. At the baseline visit, all the patients were recommended to use artificial tears (Olixia pure®, Chroma Pharma, Vienna Austria), as needed, and to continue with the same antiglaucomatous therapy. The severity of dry eye symptoms was evaluated with the Ocular Surface Disease Index questionnaire (OSDI). Tear film osmolarity was measured with the TearLab® Osmolarity System (TearLab Corp, San Diego, CA).

Results:

IOP-lowering treatment was 48,47±42,37 months (range from 10 to 169). Tear film osmolarity was 310.45±10.78 mOsms/L (range: 285-343) at baseline, and 318.16±13.05 mOsms/L and 306.45±8.14 mOsms/L at the one and three month visits, respectively. (p>0.05 for basal vs 3 month visits). No significant difference was also found in the rate of patients with hyperosmolar tears using 312 mOsms/L cut off, at any visit (p>0.05). The OSDI score was 22,04±14,22, 20,56±15,33 and 17,43±13,47 at baseline, and one and three month visits, respectively. There was a tendency to significance in the comparison of the baseline and three months visit OSDI score (p=0.1)

Conclusions:

Glaucomatous patients medically treated do have a hyperosmolar tear film on average, that seems not to change with the use of an iso-osmolar topical lubricant with hyaluronic acid. Nevertheless, the OSDI score shows a tendency to improve.

Financial Disclosure:

NONE